Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 34

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Implantation of the clinical-grade human neural stem cell line, CTX0E03 , rescues the behavioral and pathological deficits in the quinolinic acid-lesioned rodent model of Huntington's disease

Yoon, Yongwoo, Kim, Hyun Sook, Jeon, Iksoo, Noh, Jeong-Eun, Park, Hyun Jung, Lee, Suji, Park, In-Hyun, Stevanato, Lara, Hicks, Caroline, Corteling, Randolph, Barker, Roger A., Sinden, John D., Song, Jihwan·2020·Stem Cells
DOI 10.1002/stem.3191PMC PMC7496241
Open this paper in CoChat — free account

Abstract

Huntington's disease (HD) is a devastating, autosomal-dominant neurodegenerative disease, for which there are currently no disease-modifying therapies. Clinical trials to replace the damaged striatal medium spiny neurons (MSNs) have been attempted in the past two decades but have met with only limited success. In this study, we investigated whether a clonal, conditionally immortalized neural stem cell line (CTX0E03), which has already shown safety and signals of efficacy in chronic ischemic stroke patients, could rescue deficits seen in an animal model of HD. After CTX0E03 transplantation into the quinolinic acid-lesioned rat model of HD, behavioral changes were measured using the rotarod, stepping, and staircase tests. In vivo differentiation and neuronal connections of the transplanted CTX0E03 cells were evaluated with immunohistochemical staining and retrograde tracing with Fluoro-Gold. We found that transplantation of CTX0E03 gave rise to a significant behavioral improvement compared with the sham- or fibroblast-transplanted group. Transplanted CTX0E03 formed MSNs (DARPP-32) and GABAergic neurons (GABA, GAD65/67) with BDNF expression in the striatum, while cortically transplanted cells formed Tbr1-positive neurons. Using a retrograde label, we also found stable engraftment and connection of the transplanted cells with host brain tissues. CTX0E03 transplantation also reduced glial scar formation and inflammation, as well as increasing endogenous neurogenesis and angiogenesis. Overall, our results demonstrate that CTX0E03, a clinical-grade neural stem cell line, is effective for preclinical test in HD, and, therefore, will be useful for clinical development in the treatment of HD patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/stem.3191

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 CTX cells significantly improve the behavioral deficits induced by quinolinic acid (QA) lesioning of the striatum. Marked improvement of locomotor activity was observed in the QA‐lesioned rats transplanted with CTX between 8 and 12 weeks post‐transplantation (**P < .001 Sham vs CTX; ##P < .001 Fibroblast vs CTX) on rotarod (A) and stepping (B) tests. In the staircase test (C), significant behavioral improvement was observed in the QA‐lesioned rats with CTX between 8 and 12 weeks after transplantation (*P < .05 Sham vs CTX; #P < .05 Fibroblast vs CTX). Prescore represents the animals before receiving QA and the baseline score represents 7 days after QA lesioning. Subsequent scores represent animals after CTX transplantation
FIGURE 1 CTX cells significantly improve the behavioral deficits induced by quinolinic acid (QA) lesioning of the striatum. Marked improvement of locomotor activity was observed in the QA‐lesioned rats transplanted with CTX between 8 and 12 weeks post‐transplantation (**P < .001 Sham vs CTX; ##P < .001 Fibroblast vs CTX) on rotarod (A) and stepping (B) tests. In the staircase test (C), significant behavioral improvement was observed in the QA‐lesioned rats with CTX between 8 and 12 weeks after transplantation (*P < .05 Sham vs CTX; #P < .05 Fibroblast vs CTX). Prescore represents the animals before receiving QA and the baseline score represents 7 days after QA lesioning. Subsequent scores represent animals after CTX transplantationCC BY-NC-ND · PubMed Central
FIGURE 2 CTX cells can survive and differentiate into striatal neurons in the striatum of quinolinic acid (QA)‐lesioned brain 13 weeks after transplantation. A, Widespread distribution of survived CTX cells were detected using a human nuclei antibody (hNu) and visualized with DAB (3,3′‐diaminobenzidine) in the QA‐lesioned striatum. Scale bar = 50 μm. B‐E, Neuronal differentiation of CTX cells transplanted into the striatum (arrows) was identified by hNu colocalized with neuronal markers, including DARPP‐32 (B), GABA (C), GAD 65/67 (D), and BDNF (E). Scale bar = 50 μm
FIGURE 2 CTX cells can survive and differentiate into striatal neurons in the striatum of quinolinic acid (QA)‐lesioned brain 13 weeks after transplantation. A, Widespread distribution of survived CTX cells were detected using a human nuclei antibody (hNu) and visualized with DAB (3,3′‐diaminobenzidine) in the QA‐lesioned striatum. Scale bar = 50 μm. B‐E, Neuronal differentiation of CTX cells transplanted into the striatum (arrows) was identified by hNu colocalized with neuronal markers, including DARPP‐32 (B), GABA (C), GAD 65/67 (D), and BDNF (E). Scale bar = 50 μmCC BY-NC-ND · PubMed Central
FIGURE 3 CTX cells implanted in the cortex can differentiate into cortical neurons. Colocalization (yellow) of hNu and Trb1 demonstrates neuronal differentiation of CTX cells in the cortex 13 weeks after transplantation (arrows). Scale bar = 50 μm
FIGURE 3 CTX cells implanted in the cortex can differentiate into cortical neurons. Colocalization (yellow) of hNu and Trb1 demonstrates neuronal differentiation of CTX cells in the cortex 13 weeks after transplantation (arrows). Scale bar = 50 μmCC BY-NC-ND · PubMed Central
FIGURE 4 CTX cells can establish striato‐pallidal connection in the quinolinic acid (QA)‐lesioned striatum. Colocalization (yellow) of Fluoro‐Gold (FG) and human nuclei in CTX cells (arrows) within the stratum suggests some restoration of local circuitry. Scale bar = 50 μm
FIGURE 4 CTX cells can establish striato‐pallidal connection in the quinolinic acid (QA)‐lesioned striatum. Colocalization (yellow) of Fluoro‐Gold (FG) and human nuclei in CTX cells (arrows) within the stratum suggests some restoration of local circuitry. Scale bar = 50 μmCC BY-NC-ND · PubMed Central
FIGURE 5 CTX cells decrease gliosis and proinflammatory responses in the quinolinic acid (QA)‐lesioned striatum. A, GFAP staining was significantly reduced in CTX‐implanted brains compared with Sham (Media) and Fibroblast (FB) injected brains (CTX vs Sham P = .004; CTX vs FB P = .014). Scale bar = 50 μm. B, CTX cells reduce a M1 proinflammatory phenotype of macrophage in the QA‐lesioned striatum. The percentage of iNOS/ED1 was reduced in CTX treated brains compared with Sham (Media) and Fibroblast grafted brains (CTX vs Sham P < .001, CTX vs FB P = .017). C, CTX cells increase an M2 anti‐inflammatory phenotype in the QA‐lesioned striatum. CD206/ED1 increased in CTX treated brains compared with Sham (Media) and Fibroblast injected brains (CTX vs Sham P < .001, CTX vs FB P < .001). Scale bar = 50 μm
FIGURE 5 CTX cells decrease gliosis and proinflammatory responses in the quinolinic acid (QA)‐lesioned striatum. A, GFAP staining was significantly reduced in CTX‐implanted brains compared with Sham (Media) and Fibroblast (FB) injected brains (CTX vs Sham P = .004; CTX vs FB P = .014). Scale bar = 50 μm. B, CTX cells reduce a M1 proinflammatory phenotype of macrophage in the QA‐lesioned striatum. The percentage of iNOS/ED1 was reduced in CTX treated brains compared with Sham (Media) and Fibroblast grafted brains (CTX vs Sham P < .001, CTX vs FB P = .017). C, CTX cells increase an M2 anti‐inflammatory phenotype in the QA‐lesioned striatum. CD206/ED1 increased in CTX treated brains compared with Sham (Media) and Fibroblast injected brains (CTX vs Sham P < .001, CTX vs FB P < .001). Scale bar = 50 μmCC BY-NC-ND · PubMed Central
FIGURE 6 CTX cells promote neurogenesis in the quinolinic acid (QA)‐lesioned brain. Compared with Sham (Media) and Fibroblast injected brains, the proportion of both BrdU and DCX stained cells was increased markedly in the SVZ of CTX treated brains (BrdU/DAPI CTX vs Sham P < .001, CTX vs FB P < .001; DCX/DAPI CTX vs Sham P < .001, CTX vs FB P = .002). The percentage of DCX expressing cells in BrdU‐positive cells in the SVZ was also significantly increased in CTX treated brains (DCX/BrdU CTX vs Sham P = .025, CTX vs FB P = .029). Scale bar = 100 μm
FIGURE 6 CTX cells promote neurogenesis in the quinolinic acid (QA)‐lesioned brain. Compared with Sham (Media) and Fibroblast injected brains, the proportion of both BrdU and DCX stained cells was increased markedly in the SVZ of CTX treated brains (BrdU/DAPI CTX vs Sham P < .001, CTX vs FB P < .001; DCX/DAPI CTX vs Sham P < .001, CTX vs FB P = .002). The percentage of DCX expressing cells in BrdU‐positive cells in the SVZ was also significantly increased in CTX treated brains (DCX/BrdU CTX vs Sham P = .025, CTX vs FB P = .029). Scale bar = 100 μmCC BY-NC-ND · PubMed Central
FIGURE 7 CTX cells promote angiogenesis in the quinolinic acid (QA)‐lesioned brain. RECA‐1 staining demonstrates that the number of branch points and microvessels was all significantly increased in CTX‐implanted brains compared with Sham (Media) and Fibroblast injected brains (P < .001 CTX vs Sham; P < .001 CTX vs FB; branch points P = .019 CTX vs Sham; P < .001 CTX vs FB; microvessels P < .001 CTX vs Sham; P < .001 CTX vs FB). Scale bar = 50 μm
FIGURE 7 CTX cells promote angiogenesis in the quinolinic acid (QA)‐lesioned brain. RECA‐1 staining demonstrates that the number of branch points and microvessels was all significantly increased in CTX‐implanted brains compared with Sham (Media) and Fibroblast injected brains (P < .001 CTX vs Sham; P < .001 CTX vs FB; branch points P = .019 CTX vs Sham; P < .001 CTX vs FB; microvessels P < .001 CTX vs Sham; P < .001 CTX vs FB). Scale bar = 50 μmCC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 36

  1. Pringsheim, 2012, The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis, Mov Disord, 27, 1083, 10.1002/mds.25075 · DOI
  2. Connor, 2018, Concise review: the use of stem cells for understanding and treating Huntington's disease, Stem Cells, 36, 146, 10.1002/stem.2747 · DOI
  3. Dunnett, 2004, Cell therapy in Huntington's disease, NeuroRx, 1, 394, 10.1602/neurorx.1.4.394 · DOI
  4. Kim, 2015, Progress in Stem Cell Transplantation, 77
  5. Lee, 2005, Intravenous administration of human neural stem cells induces functional recovery in Huntington's disease rat model, Neurosci Res, 52, 243, 10.1016/j.neures.2005.03.016 · DOI
  6. Ryu, 2004, Proactive transplantation of human neural stem cells prevents degeneration of striatal neurons in a rat model of Huntington disease, Neurobiol Dis, 16, 68, 10.1016/j.nbd.2004.01.016 · DOI
  7. Johann, 2007, Time of transplantation and cell preparation determine neural stem cell survival in a mouse model of Huntington's disease, Exp Brain Res, 177, 458, 10.1007/s00221-006-0689-y · DOI
  8. Al-Gharaibeh, 2017, Induced pluripotent stem cell-derived neural stem cell transplantations reduced behavioral deficits and ameliorated neuropathological changes in YAC128 mouse model of Huntington's disease, Front Neurosci, 11, 628, 10.3389/fnins.2017.00628 · DOI
  9. Stroemer, 2009, The neural stem cell line CTX0E03 promotes behavioral recovery and endogenous neurogenesis after experimental stroke in a dose-dependent fashion, Neurorehabil Neural Repair, 23, 895, 10.1177/1545968309335978 · DOI
  10. Kalladka, 2016, Human neural stem cells in patients with chronic ischaemic stroke (PISCES): a phase 1, first-in-man study, Lancet, 388, 787, 10.1016/S0140-6736(16)30513-X · DOI
  11. Hicks, 2013, In vivo and in vitro characterization of the angiogenic effect of CTX0E03 human neural stem cells, Cell Transplant, 22, 1541, 10.3727/096368912X657936 · DOI
  12. Sinden, 2017, Human neural stem cell therapy for chronic ischemic stroke: charting Progress from laboratory to patients, Stem Cells Dev, 26, 933, 10.1089/scd.2017.0009 · DOI
  13. Lelos, 1780, Generating Excitotoxic lesion models of Huntington's disease, Methods Mol Biol, 2018, 209
  14. Pollock, 2006, A conditionally immortal clonal stem cell line from human cortical neuroepithelium for the treatment of ischemic stroke, Exp Neurol, 199, 143, 10.1016/j.expneurol.2005.12.011 · DOI
  15. Conte-Perales, 2010, Neuroanatomical tracing combined with in situ hybridization: analysis of gene expression patterns within brain circuits of interest, J Neurosci Methods, 194, 28, 10.1016/j.jneumeth.2009.11.021 · DOI
  16. Wojtowicz, 2006, BrdU assay for neurogenesis in rodents, Nat Protoc, 1, 1399, 10.1038/nprot.2006.224 · DOI
  17. Hanna, 2007, Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin, Science, 318, 1920, 10.1126/science.1152092 · DOI · Paper page
  18. Jeon, 2012, Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells, Stem Cells, 30, 2054, 10.1002/stem.1135 · DOI
  19. Chang, 2013, Therapeutic effect of BDNF-overexpressing human neural stem cells (HB1. F3. BDNF) in a rodent model of middle cerebral artery occlusion, Cell Transplant, 22, 1441, 10.3727/096368912X657323 · DOI
  20. Takahashi, 2007, Induction of pluripotent stem cells from adult human fibroblasts by defined factors, Cell, 131, 861, 10.1016/j.cell.2007.11.019 · DOI · Paper page
  21. Schwarcz, 1983, Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain, Science, 219, 316, 10.1126/science.6849138 · DOI
  22. Beal, 1991, Chronic quinolinic acid lesions in rats closely resemble Huntington's disease, J Neurosci, 11, 1649, 10.1523/JNEUROSCI.11-06-01649.1991 · DOI
  23. Popoli, 1994, Behavioral and electrophysiological correlates of the quinolinic acid rat model of Huntington's disease in rats, Brain Res Bull, 35, 329, 10.1016/0361-9230(94)90109-0 · DOI
  24. Francis, 2000, Behavior characterization of a model of Huntington's disease in rats, induced by quinolinic acid, Rev Neurol, 30, 1016
  25. Sanberg, 1989, The quinolinic acid model of Huntington's disease: locomotor abnormalities, Exp Neurol, 105, 45, 10.1016/0014-4886(89)90170-2 · DOI
  26. McBride, 2004, Human neural stem cell transplants improve motor function in a rat model of Huntington's disease, J Comp Neurol, 475, 211, 10.1002/cne.20176 · DOI
  27. Rosas, 2008, Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity, Brain, 131, 1057, 10.1093/brain/awn025 · DOI · Paper page
  28. Thu, 2010, Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease, Brain, 133, 1094, 10.1093/brain/awq047 · DOI
  29. Smith, 2012, Implantation site and lesion topology determine efficacy of a human neural stem cell line in a rat model of chronic stroke, Stem Cells, 30, 785, 10.1002/stem.1024 · DOI
  30. Amor, 2014, Inflammation in neurodegenerative diseases—an update, Immunology, 142, 151, 10.1111/imm.12233 · DOI · Paper page
  31. Neumann, 2009, Debris clearance by microglia: an essential link between degeneration and regeneration, Brain, 132, 288, 10.1093/brain/awn109 · DOI · Paper page
  32. Loov, 2012, Engulfing astrocytes protect neurons from contact-induced apoptosis following injury, PLoS One, 7, 10.1371/journal.pone.0033090 · DOI
  33. Mosser, 2008, Exploring the full spectrum of macrophage activation, Nat Rev Immunol, 8, 958, 10.1038/nri2448 · DOI · Paper page
  34. Mills, 2012, M1 and M2 macrophages: oracles of health and disease, Crit Rev Immunol, 32, 463, 10.1615/CritRevImmunol.v32.i6.10 · DOI
  35. Hassani, 2012, Human neural progenitor cell engraftment increases neurogenesis and microglial recruitment in the brain of rats with stroke, PLoS One, 7, 10.1371/journal.pone.0050444 · DOI
  36. Reidling, 2018, Human neural stem cell transplantation rescues functional deficits in R6/2 and Q140 Huntington's disease mice, Stem Cell Rep, 10, 58, 10.1016/j.stemcr.2017.11.005 · DOI

Cited by

See all 34

Metadata

Authors
Yoon, Y., Kim, H. S., Jeon, I., Noh, J.-E., Park, H. J., Lee, S., Park, I.-H., Stevanato, L., Hicks, C., Corteling, R., Barker, R. A., Sinden, J. D., & Song, J.
Affiliations
  • 1 Department of Biomedical Science, CHA Stem Cell Institute, CHA University, Seongnam-si, Gyeonggi-do, Republic of Korea
  • 2 Department of Neurology, CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Republic of Korea
  • 3 Department of Genetics, Yale Stem Cell Center, Yale School of Medicine, New Haven, Connecticut, USA
  • 4 ReNeuron, Pencoed Business Park, Bridgend, UK
  • 5 John van Geest Cambridge Centre for Brain Repair, Department of Clinical Neuroscience, University of Cambridge, Cambridge, UK
ORCID
Song, Jihwan
Venue
Stem Cells
Publisher
Oxford University Press (OUP)
Published
2020-05-06
Volume
38
Issue
8
Pages
936-947
ISSN
  • 1066-5099
  • 1549-4918
DOI
10.1002/stem.3191
PMC
PMC7496241
Cited by
34
References
2
Language
en
Licence
Funders
  • National Research Foundation of Korea (NRF-2017M3A9B4061407, NRF‐2017M3A9B4061407)
  • iPS Bio, Inc
  • ReNeuron, United Kingdom

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review